In summary, the current study firstly indicated that (i) there was strong association between DNMT3A genetic polymorphisms and the treatment outcomes in AML patients, and (ii) an available score model evaluating multiple polymorphisms in DNMT3A could predict chemosensitivity or prognosis in AML patients, and (iii) especially, a strategy estimating multiple noncoding polymorphisms in epigenetic modification related genes, such as DNMT3A, could predict the treatment outcomes in AML patients, which may improve rational design for more precise therapeutic regimens and prognostic stratification. Here, DNMT3A is linked to acute myeloid leukemia.